Healthy
Conditions
Brief summary
The primary objective of this study is to evaluate the pharmacokinetics (PK) profile of monomethyl fumarate (MMF) following delivery of BG00012 (dimethyl fumarate, DMF) 120 mg (Part 1) and BG00012 240 mg (Part 2) to varying regions within the GI tract in healthy volunteers. The secondary objective of this study is to evaluate the safety and tolerability profile following the delivery of BG00012 120 mg (Part 1) and BG00012 240 mg (Part 2) to varying regions within the GI tract in healthy volunteers.
Interventions
DRUGdimethyl fumarate
tablet
Sponsors
Biogen
Study design
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
Key Inclusion Criteria: * Healthy males or non-pregnant, non-lactating healthy females. * Body mass index (BMI) of 18 through 35 kg/m2. * Subjects of childbearing potential (including males) must practice effective contraception during the study and be willing and able to continue contraception for 90 days after their last dose of study treatment Key
Exclusion criteria
* History of or positive test result at Screening for human immunodeficiency virus (HIV), hepatitis C virus (HCV) antibody, or hepatitis B virus (defined as positive for hepatitis B surface antigen \[HBsAg\] or hepatitis B core antibody \[HBcAb\]). * Serious infection (e.g., pneumonia, septicemia) within the 3 months prior to first dose. * Vaccinations within 4 weeks prior to first dose. * History of drug or alcohol abuse (as defined by the Investigator) within the previous 2 years, or regular alcohol consumption in males \>21 units per week and females \>14 units per week (1 unit = ½ pint of beer, 25 mL of 40% spirit or a 125 mL glass of wine). * History of clinically significant gastrointestinal (GI) disease as determined by the Investigator (including Crohn's Disease, Ulcerative Colitis, confirmed diagnosis of active Irritable Bowel Syndrome). * History of any clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, and renal, or other major disease, as determined by the Investigator. NOTE: Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the plasma concentration versus time curve (AUC) ratio of test regimens compared with reference for Part 2 | Up to week 9 |
| The maximum observed concentration: Cmax | Up to week 9 |
| The time to reach maximum observed concentration: Tmax | Up to week 9 |
| The area under the plasma concentration versus time curve from time zero to 24 hours | Up to week 9 |
| The area under the plasma concentration versus time curve from time zero to time t (the last sampling time with quantifiable monomethyl fumarate [MMF]) | Up to week 9 |
| The area under the plasma concentration versus time curve from time zero to infinity | Up to week 9 |
| The apparent elimination half-life | Up to week 9 |
| The time prior to the first quantifiable monomethyl fumarate (MMF) plasma concentration | Up to week 9 |
| Area under the plasma concentration versus time curve (AUC) ratio of test regimens compared with reference for Part 1 | Up to week 9 |
Secondary
| Measure | Time frame |
|---|---|
| The number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs) | Up to week 9 |
Countries
United Kingdom
Outcome results
None listed